Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.37 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487754 | 0.97 | ALOX5AP (0.36) | ALOX5APFEN1PDK2PIM1SLC6A2 | |
| SCHEMBL13487897 | 0.97 | PDK2 (0.38) | ALOX5APFEN1PDK2PIM1SLC6A2 | |
| SCHEMBL13488053 | 0.94 | CYP11B2 (0.36) | ALOX5APFEN1PDK2PIM1PIM3 | |
| SCHEMBL13487808 | 0.92 | ALOX5AP (0.36) | ALOX5APFEN1PDK2PIM1SLC6A2 | |
| SCHEMBL13487982 | 0.92 | ALOX5AP (0.36) | ALOX5APFEN1PDK2PIM1SLC6A2 | |
| SCHEMBL13487356 | 0.91 | ALOX5AP (0.35) | ALOX5APFEN1PDK2PIM1SLC6A2 | |
| SCHEMBL13487516 | 0.91 | PDK2 (0.35) | ALOX5APFEN1PDK2PIM1PIM3 | |
| SCHEMBL13487686 | 0.89 | CYP11B1 (0.36) | ALOX5APFEN1PDK2PIM1 | |
| SCHEMBL13488125 | 0.88 | PDK2 (0.44) | PDK2 | |
| SCHEMBL13487448 | 0.87 | ALOX5AP (0.34) | ALOX5APFEN1PDK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | ALOX5AP 230/4885FEN1 1389/4885PDK2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.